marked.bio

Company

Chipscreen Biosciences

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. A Study of NWY001 in Subjects With Advanced Solid Tumors

    Recruiting Phase 1 Chipscreen Biosciences Started 2024Primary completion 2026-01 NCT05979155

    NWY001

    For part 2f: Participant has a diagnosis of histologically confirmed advanced MSI-H/dMMR colorectal cancer

    MSI-H / dMMRStatus may be outdated, last updated 2024-07-16Advanced Solid Tumor

  2. A Study of CS23546 in Subjects With Advanced Tumors

    Recruiting Phase 1 Chipscreen Biosciences Started 2024Primary completion 2027-02 NCT06245122

    CS23546

    Cohort 4, Subjects with PD-L1 expression positive and/or microsatellite-instability-high (MSI-H) / mismatch-repair-deficient (dMMR) advanced solid tumors or lymphoma

    MSI-H / dMMRAdvanced Tumors